GlassScriptPhysician profile
Gene H Kim
NPI 1598923005
$8,503.57
in general payments reported to CMS, 2019-2025
32 companies · $721 in 2025
The $721 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,042 · 2020: $710 · 2021: $874 · 2022: $1,967 · 2023: $1,255 · 2024: $935 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,886 · Travel and Lodging: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,885.80 |
| Travel and Lodging | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,075.29 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Ancora Heart, INC. | $1,238.00 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $700.23 | 2019-2024 | Lifevest |
| Cvrx, INC. | $590.93 | 2021-2025 | Barostim Neo System |
| Medtronic Vascular, INC. | $346.54 | 2019 | |
| Pfizer INC. | $234.84 | 2019-2023 | |
| Medtronic, INC. | $192.15 | 2024 | Selectsecure, Cobalt Dr Mri Surescan |
| Paragonix Technologies, INC. | $138.11 | 2024 | Baroguard, Pancreaspak, Sherpapak |
| E.R. Squibb & Sons, L.L.C. | $128.72 | 2022-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $96.63 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $86.93 | 2022-2025 | Farxiga, Brilinta |
| Amgen INC. | $86.88 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $69.60 | 2022-2023 | Verquvo |
| Portola Pharmaceuticals, LLC | $64.10 | 2019 | |
| Daiichi Sankyo INC. | $51.17 | 2023 | Injectafer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $45.33 | 2025 | Attruby |
| Scpharmaceuticals INC. | $44.23 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.85 | 2023 | Jardiance |
| Zoll Circulation INC | $35.36 | 2021 | |
| United Therapeutics Corporation | $29.58 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $27.76 | 2020 | |
| Procyrion, INC. | $26.81 | 2022 | |
| Phathom Pharmaceuticals, INC. | $26.08 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $24.47 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.33 | 2023 | Livtencity |
| Akcea Therapeutics, INC. | $21.39 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.01 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.08 | 2023 | Inpefa |
| Kestra Medical Technology Services, INC. | $14.34 | 2025 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $12.83 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.